20/20 Biolabs Inc. (AIDX) vs GRI Bio, Inc. (GRI)
A side-by-side comparison of 20/20 Biolabs Inc. and GRI Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AIDX
20/20 Biolabs Inc.
$0.35HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
GRI
GRI Bio, Inc.
$1.90HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AIDX vs GRI
growth of $100 · dividends reinvested · last 1yAIDX -98.5% (-98.5%/yr)GRI -26.9% (-26.9%/yr)GRI compounded faster over this window
Log scale — wide-divergence pair
AIDX GRI
Metrics side by side
Total return (annualized)
| Metric | AIDX | GRI |
|---|---|---|
| Total return (1Y) | N/A | -96.44% |
| Total return CAGR (3Y) | N/A | -97.04% |
| Total return CAGR (5Y) | N/A | -95.39% |
GRI is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.